Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Biocardia Inc (BCDA)

Biocardia Inc (BCDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates Zacks - Wed May 10, 2023

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BCDA : 0.3795 (+0.93%)
EVGN : 0.6695 (+1.49%)
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates Zacks - Tue May 9, 2023

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -26.83% and 62.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

MRSN : 2.88 (-10.28%)
BCDA : 0.3795 (+0.93%)
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates Zacks - Thu May 4, 2023

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 73.12 (-1.20%)
BCDA : 0.3795 (+0.93%)
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure Business Wire - Tue Dec 6, 2022

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration (FDA) approval...

BCDA : 0.3795 (+0.93%)
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates Zacks - Wed Nov 9, 2022

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BCDA : 0.3795 (+0.93%)
URGN : 14.21 (-2.20%)
BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know Zacks - Wed Nov 9, 2022

BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BCDA : 0.3795 (+0.93%)
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates Zacks - Tue Nov 8, 2022

Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ALEC : 5.25 (-1.69%)
BCDA : 0.3795 (+0.93%)
BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results Globe Newswire - Wed Aug 10, 2022

SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 0.3795 (+0.93%)
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates Zacks - Mon Aug 8, 2022

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -38.24% and 5.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

YMAB : 15.29 (-0.33%)
BCDA : 0.3795 (+0.93%)
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022 Globe Newswire - Thu Aug 4, 2022

SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 0.3795 (+0.93%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip Barchart - Wed Apr 24, 6:30PM CDT
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot